Trial record 1 of 1 for:    NCT01689519
Previous Study | Return to List | Next Study

coBRIM: A Phase 3 Study Comparing GDC-0973 (Cobimetinib), a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche
ClinicalTrials.gov Identifier:
NCT01689519
First received: September 18, 2012
Last updated: October 20, 2014
Last verified: October 2014
  Purpose

This multicenter, randomized, double-blind, placebo-controlled phase 3 study wil l evaluate the safety and efficacy of vemurafenib alone and vemurafenib in combi nation with GDC-0973 (cobimetinib), a MEK inhibitor, in previously untreated BRA F V600 mutation-positive patients with unresectable locally advanced or metastat ic melanoma. Patients will be randomized to one of two treatment arms, Arm A: ve murafenib 960 mg twice a day (days 1-28 of each cycle) and placebo (days 1-21 of each cycle); Arm B: vemurafenib 960 mg twice a day (days 1-28 of each cycle) an d GDC-0973 (cobimetinib) 60 mg once daily (days 1-21 of each cycle). Patients wi ll receive treatment until disease progression, unacceptable toxicity or withdra wal of consent.


Condition Intervention Phase
Malignant Melanoma
Drug: GDC-0973 (cobimetinib)
Drug: Placebo
Drug: vemurafenib
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF VEMURAFENIB VERSUS VEMURAFENIB PLUS GDC-0973 (COBIMETINIB) IN PREVIOUSLY UNTREATED BRAFV600-MUTATION POSITIVE PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA

Resource links provided by NLM:


Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • Progression-free survival according to Response Evaluation Criteria in Solid Tumors v1.1 [ Time Frame: Approximately 5 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Overall survival [ Time Frame: Approximately 5 years ] [ Designated as safety issue: No ]
  • Objective response rate according to Response Evaluation Criteria in Solid Tumors v1.1 [ Time Frame: Approximately 5 years ] [ Designated as safety issue: No ]
  • Duration of response according to Response Evaluation Criteria in Solid Tumors v1.1 [ Time Frame: Approximately 5 years ] [ Designated as safety issue: No ]
  • Safety: incidence of adverse events [ Time Frame: Approximately 5 years ] [ Designated as safety issue: No ]
  • Pharmacokinetics: Area under the plasma concentration time curve trough 24 hours [ Time Frame: Cycle 1, days 1 and 15; cycle 2, day 15 ] [ Designated as safety issue: No ]
  • Pharmacokinetics: Minimum observed plasma concentration [ Time Frame: Cycle 1, days 1 and 15; cycle 2, day 15 ] [ Designated as safety issue: No ]
  • Pharmacokinetics: Apparent clearance following oral dosing [ Time Frame: Cycle 1, days 1 and 15; cycle 2, day 15 ] [ Designated as safety issue: No ]
  • Quality of life as measured by the European Organization for Research and Cancer Quality of Life Questionnaire (QLQ-30) [ Time Frame: Approximately 5 years ] [ Designated as safety issue: No ]
  • Quality of life as measured by the EuroQol 5 dimension (EQ-5D) [ Time Frame: Approximately 5 years ] [ Designated as safety issue: No ]

Enrollment: 499
Study Start Date: January 2013
Estimated Study Completion Date: December 2017
Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Control Arm Drug: Placebo
Placebo orally once a day on days 1-21 of each 28-day treatment cycle. Treatment will be administered until disease progression, unacceptable toxicity or withdrawal of consent
Drug: vemurafenib
960 mg orally twice a day on days 1-28 of each 28-day cycle. Treatment will be administered until disease progression, unacceptable toxicity or withdrawal of consent
Experimental: Investigational Arm Drug: GDC-0973 (cobimetinib)
60 mg orally once a day on days 1-21 of each 28-day treatment cycle. Treatment will be administered until disease progression, unacceptable toxicity or withdrawal of consent
Drug: vemurafenib
960 mg orally twice a day on days 1-28 of each 28-day cycle. Treatment will be administered until disease progression, unacceptable toxicity or withdrawal of consent

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with histologically confirmed melanoma, either unresectable stage IIIc or stage IV metastatic melanoma, as defined by the American Joint Committee on Cancer 7th edition.
  • Unresectability of stage IIIc disease must have confirmation from a surgical oncologist.
  • Patients must be naïve to treatment for locally advanced unresectable or metastatic disease (i.e., no prior systemic anti-cancer therapy for advanced disease; stage IIIc and IV). Prior adjuvant immunotherapy (including ipilimumab) is allowed.
  • Documentation of BRAFV600 mutation-positive status in melanoma tumor tissue (archival or newly obtained tumor samples) using the cobas 4800 BRAF V600 mutation test.
  • Measurable disease per RECIST v1.1.
  • Eastern Clinical Oncology Group performance status of 0 or 1.
  • Consent to provide archival for biomarker analyses.
  • Consent to undergo tumor biopsies for biomarker analyses.
  • Life expectancy >/= 12 weeks.
  • Adequate hematologic and end organ function

Exclusion Criteria:

  • History of prior RAF or MEK pathway inhibitor treatment.
  • Palliative radiotherapy within 14 days prior to the first dose of study treatment.
  • Major surgery or traumatic injury within 14 days prior to first dose of study treatment.
  • Active malignancy other than melanoma that could potentially interfere with the interpretation of efficacy measures. Patients with a previous malignancy within the past 3 years are excluded except for patients with resected basal cell carcinoma (BCC) or squamous cell carcinoma (SCC) of the skin, melanoma in-situ, carcinoma in-situ of the cervix, and carcinoma in-situ of the breast.
  • History of or evidence of retinal pathology on ophthalmologic examination that is considered a risk factor for neurosensory retinal detachment, retinal vein occlusion (RVO), or neovascular macular degeneration.
  • Uncontrolled glaucoma with intra-ocular pressures
  • Serum cholesterol >/= Grade 2
  • Hypertriglyceridemia >/= Grade 2
  • Hyperglycemia (fasting) >/= Grade 2
  • History of clinically significant cardiac dysfunction
  • Patients with active CNS lesions (including carcinomatous meningitis) are excluded. However, patients are eligible if:

    1. All known CNS lesions have been treated with stereotactic therapy or surgery, AND
    2. There has been no evidence of clinical and radiographic disease progression in the CNS for >/= 3 weeks after radiotherapy or surgery
  • Current severe, uncontrolled systemic disease.
  • History of malabsorption or other condition that would interfere with absorption of study drugs.
  • Pregnant, lactating, or breast feeding.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01689519

  Show 193 Study Locations
Sponsors and Collaborators
Hoffmann-La Roche
Investigators
Study Director: Clinical Trials Hoffmann-La Roche
  More Information

No publications provided

Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT01689519     History of Changes
Other Study ID Numbers: GO28141, 2012-003008-11
Study First Received: September 18, 2012
Last Updated: October 20, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Hoffmann-La Roche:
Zelboraf
vemurafenib
RG7204
PLX4032
Genentech MEK inhibitor
Genentech BRAF inhibitor
Roche MEK inhibitor
Roche BRAF inhibitor
RO5185426
metastatic melanoma
BRAF positive melanoma
BRAF mutant melanoma
advanced melanoma
Genentech RAF inhibitor
Roche RAF inhibitor
BRAF V600E kinase inhibitor
Oncogenic BRAF inhibitor
BRAF kinase inhibitor
GDC-0973
XL518
melanoma

Additional relevant MeSH terms:
Melanoma
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Neuroectodermal Tumors
Neuroendocrine Tumors
Nevi and Melanomas

ClinicalTrials.gov processed this record on October 23, 2014